Vision, retinal thickness, and foveal avascular zone size after intravitreal bevacizumab for diabetic macular edema

Advances in Therapy

Volumn 29, Issue 4, 2012, Pages 359-369

  Erol, Nazmiye ^a   Gursoy, Huseyin ^a   Kimyon, Sabit ^a   Topbas, Seyhan ^a   Colak, Ertugrul ^a  

^a OSMANGAZI UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Bevacizumab; Central macular thickness; Diabetic macular edema; Diabetic retinopathy; Foveal avascular zone; Intravitreal injection; Visual acuity

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE;

ADULT; ARTICLE; CENTRAL MACULAR THICKNESS; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DISEASE SEVERITY; DRUG EFFECT; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOVEAL AVASCULAR ZONE SIZE; HUMAN; LASER COAGULATION; MALE; OPTICAL COHERENCE TOMOGRAPHY; PROSPECTIVE STUDY; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETIC RETINOPATHY; FEMALE; FOVEA CENTRALIS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINA; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84863716839     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-012-0009-9     Document Type: Article

References (29)

1. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82:844-51. (Pubitemid 39573742)
2. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363-72.e5.
3. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113:1695.e1-15.
4. Van Meter ME, Kim ES. Bevacizumab: current updates in treatment. Curr Opin Oncol. 2010;22:586-91.
5. Erol N, Gürsoy H, Sahin A, Basmak H. Intravitreal bevacizumab following laser therapy for severe retinopathy of prematurity. J Pediatr Ophthalmol Strabismus. 2010;47:e1-4.
6. Salinas-Alamán A, Zarranz-Ventura J, Caire González- Jauregui JM, Sádaba-Echarri LM, Barrio-Barrio J, García-Layana A. Intravitreal bevacizumab associated with grid laser photocoagulation in macular edema secondary to branch retinal vein occlusion. Eur J Ophthalmol. 2011;21:434-9.
7. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina. 2005;25:111-8. (Pubitemid 40365933)
8. Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology. 1984;91:1-9. (Pubitemid 14184710)
9. Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796-806.
10. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology. 1991;98:1594-602.
11. Kook D, Wolf A, Kreutzer T, et al. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina. 2008;28:1053-60.
12. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina. 2006;26:999-1005. (Pubitemid 44973218)
13. Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology. 2007;114:743-50.
14. Lee SJ, Koh HJ. Enlargement of the foveal avascular zone in diabetic retinopathy after adjunctive intravitreal bevacizumab (avastin) with pars plana vitrectomy. J Ocul Pharmacol Ther. 2009;25:173-4.
15. Chen E, Hsu J, Park CH. Acute visual acuity loss following intravitreal bevacizumab for diabetic macular edema. Ophthalmic Surg Lasers Imaging. 2009;40:68-70.
16. Goel N, Kumar V, Ghosh B. Ischemic maculopathy following intravitreal bevacizumab for refractory diabetic macular edema. Int Ophthalmol. 2011;31:39-42.
17. Chung EJ, Roh MI, Kwon OW, Koh HJ. Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema. Retina. 2008;28:957-63.
18. Solaiman KA, Diab MM, Abo-Elenin M. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema. Retina. 2010;30:1638-45.
19. Diabetic Retinopathy Clinical Research Network, Browning DJ, Glassman AR, Aiello LP, et al. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology. 2007;114:525-36.
20. Sakata K, Funatsu H, Harino S, Noma H, Hori S. Relationship of macular microcirculation and retinal thickness with visual acuity in diabetic macular edema. Ophthalmology. 2007;114:2061-9. (Pubitemid 350016351)
21. Soheilian M, Ramezani A, Bijanzadeh B, et al. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina. 2007;27:1187-95. (Pubitemid 350211523)
22. Mansour AM. Measuring fundus landmarks. Invest Ophthalmol Vis Sci. 1990;31:41-2. (Pubitemid 20042462)
23. Bird AC, Weale RA. On the retinal vasculature of the human fovea. Exp Eye Res. 1974;19:409-17.
24. Mansour AM, Schachat A, Bodiford G, Haymond R. Foveal avascular zone in diabetes mellitus. Retina. 1993;13:125-8. (Pubitemid 23177776)
25. Arend O, Wolf S, Jung F, et al. Retinal microcirculation in patients with diabetes mellitus: dynamic and morphological analysis of perifoveal capillary network. Br J Ophthalmol. 1991;75:514-8.
26. Conrath J, Giorgi R, Raccah D, Ridings B. Foveal avascular zone in diabetic retinopathy: quantitative vs qualitative assessment. Eye (Lond). 2005;19:322-6. (Pubitemid 40484828)
27. Michaelides M, Fraser-Bell S, Hamilton R, et al. Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt Study): Report 1. Retina. 2010;30:781-6.
28. Conrath J, Giorgi R, Ridings B, Raccah D. Metabolic factors and the foveal avascular zone of the retina in diabetes mellitus. Diabetes Metab. 2005;31:465-70. (Pubitemid 41639969)
29. Sander B, Larsen M, Engler C, Lund-Andersen H, Parving HH. Early changes in diabetic retinopathy: capillary loss and blood-retina barrier permeability in relation to metabolic control. Acta Ophthalmol (Copenh). 1994;72:553-9. (Pubitemid 24370763)